Shao-Lee Lin, Acelyrin CEO

September 11, 2023 04:05 PM EDTUpdated 04:47 PM

Acelyrin's IL-17 inhibitor fails to hit primary endpoint in key study after splashy IPO

Kyle LaHucik

Biotech Correspondent

Lei Lei Wu

News Reporter

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

A new dawn for psychedelics? Compass could be the first to find out

Updated: MD Anderson-allied investment firm targets $250M for second cancer biotech fund

The fate of Moderna’s next-gen Covid shot looms large after a flurry of policy changes

Weeks after TIGIT fail, iTeos decides to wind down

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation